510(K) CLEARANCES 84 ▲14RECALLS POSTED 39 ▲27CLASS I 6 ▲2PMA DECISIONS 47 ▲11WEEK ENDING / FDA DATA AS OF
Medical Device
ManufacturingTHE TRADE PAPER OF THE FACTORY FLOOR
SUBSCRIBE / SIGN IN
K993131Substantially Equivalent

Nycocard Hba1c Glycosylated Hemoglobin Assay

Trinity Biotech (Primus Corporation dba Trinity Biotech), Kansas City MO / Traditional, Substantially Equivalent
FDA source (opens on fda.gov)

K993131 is the FDA 510(k) clearance record for NYCOCARD HBA1C GLYCOSYLATED HEMOGLOBIN ASSAY, a class II device, cleared for Primus, Inc. on under FDA product code LCP (Assay, Glycosylated Hemoglobin). FDA records list 16 510(k) clearances for Trinity Biotech (Primus Corporation dba Trinity Biotech), from to . As of , FDA records show no recalls naming K993131.

Clearance record

Decision date
Received
(245 days to decision)
Product code
LCP Assay, Glycosylated Hemoglobin
Regulation
21 CFR 864.7470
Device class
Class II
Review panel
Hematology
Applicant
Primus, Inc. 4747 Troost, Kansas City MO
510(k) summary
Statement
Third party review
No

Clearances, product code LCP

Trailing 12 months

FDA records hold no clearances under product code LCP in the trailing twelve months.

FDA records show no clearances under product code LCP in the twelve months to October 2026.
Show the numbers
Monthly 510(k) clearances under FDA product code LCP, trailing twelve months
MonthClearances
November 20250
December 20250
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260
August 20260
September 20260
October 20260